文献速递消化系统肿瘤妇科肿瘤泌尿男性生殖肿瘤

染色质组织与癌症预后:一项泛癌研究

Chromatin organisation and cancer prognosis: a pan-cancer study.
PubMed 文献 · Lancet Oncol · 2018-02-03

该研究利用机器学习分析肿瘤细胞核DNA染色图像的染色质组织,在390例I-II期结直肠癌患者中开发出染色质异质性标志物Nucleotyping,并在六个独立队列(包括结直肠癌、卵巢癌、子宫肉瘤、前列腺癌和子宫内膜癌)中验证其预后价值。结果显示,染色质异质性肿瘤患者的癌症特异性生存更差,且在多变量分析中多数队列中仍具预后意义。

要点

  • Nucleotyping可自动检测染色质异质性,并在多癌种中验证其预后价值。
  • 染色质异质性患者癌症特异性生存更差,多变量分析中多数队列仍显著。
  • 可能用于识别高危II期结直肠癌患者,辅助化疗决策。

核心结论

  • 染色质异质性标志物Nucleotyping在不同生物学和技术条件下均能一致预测预后,可可靠用于常规临床实践。

研究设计与样本

  • 验证队列包括六个独立队列:442例I或II期结直肠癌(Gloucester研究)、391例II期结直肠癌(QUASAR 2试验)、246例I期卵巢癌、354例子宫肉瘤、307例前列腺癌和791例子宫内膜癌。
  • 主要结局为癌症特异性生存。

临床怎么用

  • Nucleotyping可可靠评估染色质异质性,辅助临床决策。
  • 可识别可能从辅助化疗中获益的高危II期结直肠癌患者。

局限性

  • 需临床试验评估以Nucleotyping指导治疗决策的生存获益和成本效益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chromatin organisation affects gene expression and regional mutation frequencies and contributes to carcinogenesis. Aberrant organisation of DNA has been correlated with cancer prognosis in analyses of the chromatin component of tumour cell nuclei using image texture analysis. As yet, the methodology has not been sufficiently validated to permit its clinical application. We aimed to define and validate a novel prognostic biomarker for the automatic detection of heterogeneous chromatin organisation. METHODS: Machine learning algorithms analysed the chromatin organisation in 461 000 images of tumour cell nuclei stained for DNA from 390 patients (discovery cohort) treated for stage I or II colorectal cancer at the Aker University Hospital (Oslo, Norway). The resulting marker of chromatin heterogeneity, termed Nucleotyping, was subsequently independently validated in six patient cohorts: 442 patients with stage I or II colorectal cancer in the Gloucester Colorectal Cancer Study (UK); 391 patients with stage II colorectal cancer in the QUASAR 2 trial; 246 patients with stage I ovarian carcinoma; 354 patients with uterine sarcoma; 307 patients with prostate carcinoma; and 791 patients with endometrial carcinoma. The primary outcome was cancer-specific survival. FINDINGS: In all patient cohorts, patients with chromatin heterogeneous tumours had worse cancer-specific survival than patients with chromatin homogeneous tumours (univariable analysis hazard ratio [HR] 1·7, 95% CI 1·2-2·5, in the discovery cohort; 1·8, 1·0-3·0, in the Gloucester validation cohort; 2·2, 1·1-4·5, in the QUASAR 2 validation cohort; 3·1, 1·9-5·0, in the ovarian carcinoma cohort; 2·5, 1·8-3·4, in the uterine sarcoma cohort; 2·3, 1·2-4·6, in the prostate carcinoma cohort; and 4·3, 2·8-6·8, in the endometrial carcinoma cohort). After adjusting for established prognostic patient characteristics in multivariable analyses, Nucleotyping was prognostic in all cohorts except for the prostate carcinoma cohort (HR 1·7, 95% CI 1·1-2·5, in the discovery cohort; 1·9, 1·1-3·2, in the Gloucester validation cohort; 2·6, 1·2-5·6, in the QUASAR 2 cohort; 1·8, 1·1-3·0, for ovarian carcinoma; 1·6, 1·0-2·4, for uterine sarcoma; 1·43, 0·68-2·99, for prostate carcinoma; and 1·9, 1·1-3·1, for endometrial carcinoma). Chromatin heterogeneity was a significant predictor of cancer-specific survival in microsatellite unstable (HR 2·9, 95% CI 1·0-8·4) and microsatellite stable (1·8, 1·2-2·7) stage II colorectal cancer, but microsatellite instability was not a significant predictor of outcome in chromatin homogeneous (1·3, 0·7-2·4) or chromatin heterogeneous (0·8, 0·3-2·0) stage II colorectal cancer. INTERPRETATION: The consistent prognostic prediction of Nucleotyping in different biological and technical circumstances suggests that the marker of chromatin heterogeneity can be reliably assessed in routine clinical practice and could be used to objectively assist decision making in a range of clinical settings. An immediate application would be to identify high-risk patients with stage II colorectal cancer who might have greater absolute benefit from adjuvant chemotherapy. Clinical trials are warranted to evaluate the survival benefit and cost-effectiveness of using Nucleotyping to guide treatment decisions in multiple clinical settings. FUNDING: The Research Council of Norway, the South-Eastern Norway Regional Health Authority, the National Institute for Health Research, and the Wellcome Trust.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Kleppe A, Albregtsen F, Vlatkovic L, et al. Chromatin organisation and cancer prognosis: a pan-cancer study. Lancet Oncol. 2018. PMID: 29402700. doi:10.1016/S1470-2045(17)30899-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。